More beef in the gene editing space

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Morning! Today, more beef in the gene editing space, with Prime Medicine’s CEO getting a little aggressive over patent disputes. Also, Novartis acquires a gene editing startup, and why patient advocates are migrating to Bluesky.

Prime Medicine plans to aggressively prosecute patent infringement

From STAT’s Jason Mast: Prime Medicine CEO Keith Gottesdiener told investors last week that he would prosecute Prime’s gene editing patents “very” aggressively in the future.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$20

for 3 months, then $399/year

$20 for 3 months Get Started

Then $399/year

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

Log In